1.7299
price down icon3.28%   -0.0501
 
loading
前日終値:
$1.78
開ける:
$1.8
24時間の取引高:
440.25K
Relative Volume:
0.23
時価総額:
$519.84M
収益:
$6.23M
当期純損益:
$-95.90M
株価収益率:
-4.4356
EPS:
-0.39
ネットキャッシュフロー:
$-68.47M
1週間 パフォーマンス:
-7.93%
1か月 パフォーマンス:
-13.05%
6か月 パフォーマンス:
+63.97%
1年 パフォーマンス:
+13.27%
1日の値動き範囲:
Value
$1.70
$1.8334
1週間の範囲:
Value
$1.655
$1.89
52週間の値動き範囲:
Value
$0.6513
$2.17

Precigen Inc Stock (PGEN) Company Profile

Name
名前
Precigen Inc
Name
セクター
Healthcare (1172)
Name
電話
301-556-9900
Name
住所
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Name
職員
202
Name
Twitter
@precigen
Name
次回の収益日
2025-03-12
Name
最新のSEC提出書
Name
PGEN's Discussions on Twitter

PGEN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
PGEN
Precigen Inc
1.7299 519.84M 6.23M -95.90M -68.47M -0.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.90 130.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
681.25 75.53B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.25 35.07B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
240.05 31.72B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.38 26.76B 3.32B -860.46M -1.04B -8.32

Precigen Inc Stock (PGEN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-03-22 ダウングレード JP Morgan Neutral → Underweight
2023-05-23 開始されました JP Morgan Neutral
2022-11-18 開始されました Cantor Fitzgerald Overweight
2021-02-25 開始されました Stifel Buy
2021-02-22 開始されました Wells Fargo Overweight
2021-02-18 開始されました B. Riley Securities Buy
2020-05-08 開始されました H.C. Wainwright Buy
すべてを表示

Precigen Inc (PGEN) 最新ニュース

pulisher
08:05 AM

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th - Longview News-Journal

08:05 AM
pulisher
Mar 11, 2025

Exploring High Growth Tech Stocks In The US Market - Simply Wall St

Mar 11, 2025
pulisher
Mar 11, 2025

Analysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $7.00 - MarketBeat

Mar 11, 2025
pulisher
Mar 11, 2025

Precigen, Inc. (NASDAQ:PGEN) Stock Holdings Increased by Rhumbline Advisers - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Precigen (PGEN) Projected to Post Earnings on Tuesday - Defense World

Mar 11, 2025
pulisher
Mar 05, 2025

Is Precigen Inc’s (NASDAQ:PGEN) Stock On The Decline? - Stocks Register

Mar 05, 2025
pulisher
Mar 01, 2025

Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey

Mar 01, 2025
pulisher
Mar 01, 2025

Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 - Insider Monkey

Mar 01, 2025
pulisher
Mar 01, 2025

Precigen (NASDAQ:PGEN) Shares Gap UpWhat's Next? - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Precigen (NASDAQ:PGEN) Shares Up 7.7%Time to Buy? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement (PGEN) - Seeking Alpha

Feb 28, 2025
pulisher
Feb 26, 2025

FDA advances Precigen’s gene therapy for respiratory disease By Investing.com - Investing.com Australia

Feb 26, 2025
pulisher
Feb 26, 2025

FDA Accepts for Review Precigen RRP Gene Therapy Candidate - Genetic Engineering & Biotechnology News

Feb 26, 2025
pulisher
Feb 25, 2025

Stifel maintains Precigen stock Buy rating, $7 target post-FDA update - Investing.com Australia

Feb 25, 2025
pulisher
Feb 25, 2025

FDA Accepts BLA for Precigen’s Recurrent Respiratory Papillomatosis Gene Therapy PRGN-2012 With Priority Review - CGTLive™

Feb 25, 2025
pulisher
Feb 25, 2025

Decades in, this Germantown biopharma is on the cusp of bringing its first product to market - The Business Journals

Feb 25, 2025
pulisher
Feb 25, 2025

Precigen gets FDA Priority Review for its respiratory tract tumor treatment - MSN

Feb 25, 2025
pulisher
Feb 25, 2025

Stifel maintains Precigen stock Buy rating, $7 target post-FDA update By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Precigen Says FDA Accepts for Priority Review Application for Recurrent Respiratory Papillomatosis Treatment - Marketscreener.com

Feb 25, 2025
pulisher
Feb 25, 2025

Precigen shares surge on FDA priority review for PRGN-2012 By Investing.com - Investing.com Australia

Feb 25, 2025
pulisher
Feb 25, 2025

FDA advances Precigen's gene therapy for respiratory disease By Investing.com - Investing.com Canada

Feb 25, 2025
pulisher
Feb 25, 2025

Precigen shares surge on FDA priority review for PRGN-2012 - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

FDA advances Precigen's gene therapy for respiratory disease - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

FDA advances Precigen’s gene therapy for respiratory disease - Investing.com

Feb 25, 2025
pulisher
Feb 25, 2025

Precigen Gets FDA Priority Review of Recurrent Respiratory Papillomatosis Treatment - MarketWatch

Feb 25, 2025
pulisher
Feb 25, 2025

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 - PR Newswire

Feb 25, 2025
pulisher
Feb 25, 2025

Should You Invest in Precigen (PGEN)? - MSN

Feb 25, 2025
pulisher
Feb 20, 2025

Precigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy? - Nasdaq

Feb 20, 2025
pulisher
Feb 20, 2025

Precigen (NASDAQ:PGEN) Reaches New 1-Year HighHere's What Happened - MarketBeat

Feb 20, 2025
pulisher
Feb 19, 2025

Precigen (NASDAQ:PGEN) Stock Price Up 8.4%What's Next? - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Precigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Analysts Set Precigen, Inc. (NASDAQ:PGEN) PT at $7.00 - Armenian Reporter

Feb 19, 2025
pulisher
Feb 18, 2025

Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Price Target from Brokerages - Defense World

Feb 17, 2025
pulisher
Feb 16, 2025

Precigen (NASDAQ:PGEN) Hits New 52-Week HighHere's What Happened - MarketBeat

Feb 16, 2025
pulisher
Feb 14, 2025

Will Precigen's Treatment For Recurrent Respiratory Papillomatosis Cross The FDA Finish Line? - RTTNews

Feb 14, 2025
pulisher
Feb 14, 2025

SG Americas Securities LLC Acquires 12,578 Shares of Precigen, Inc. (NASDAQ:PGEN) - Defense World

Feb 14, 2025
pulisher
Feb 12, 2025

PGEN Stock Soars to 52-Week High, Reaching $1.93 Amid Growth - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

Precigen, Inc. (NASDAQ:PGEN) Shares Bought by Iridian Asset Management LLC CT - MarketBeat

Feb 12, 2025
pulisher
Feb 11, 2025

These Numbers Prove Just How Vibrant The Precigen Inc (NASDAQ: PGEN) Stock Has Been - Stocks Register

Feb 11, 2025
pulisher
Feb 11, 2025

Precigen (NASDAQ:PGEN) Shares Up 7.8%Here's Why - MarketBeat

Feb 11, 2025
pulisher
Feb 10, 2025

Precigen stock slides after pricing stock offering to raise $30 million - MSN

Feb 10, 2025
pulisher
Feb 10, 2025

Exploring 3 High Growth Tech Stocks in the United States - Simply Wall St

Feb 10, 2025
pulisher
Feb 10, 2025

Precigen Inc (NASDAQ: PGEN): Performance Review And Forecast - Marketing Sentinel

Feb 10, 2025
pulisher
Feb 10, 2025

Precigen: Successful Proof Of Platform, But Cash Worries Remain (NASDAQ:PGEN) - Seeking Alpha

Feb 10, 2025

Precigen Inc (PGEN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Precigen Inc (PGEN) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
KIRK RANDAL J
Director
Aug 09 '24
Buy
0.85
23,529,411
19,999,999
64,547,214
$36.89
price up icon 5.68%
$306.88
price up icon 0.65%
$32.96
price up icon 1.36%
$20.41
price up icon 1.05%
$102.19
price up icon 1.10%
biotechnology ONC
$247.47
price down icon 0.28%
大文字化:     |  ボリューム (24 時間):